{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:35:44Z","timestamp":1772865344799,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["This study was funded by GlaxoSmithKline"],"award-info":[{"award-number":["This study was funded by GlaxoSmithKline"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["which had no role in the decision of the content of the article."],"award-info":[{"award-number":["which had no role in the decision of the content of the article."]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Ther Perspect"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40267-024-01126-0","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:09:12Z","timestamp":1736964552000},"page":"34-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Expanding the coverage of herpes zoster vaccination recommendations in European countries: the example of Portugal"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-5650","authenticated-orcid":false,"given":"Sofia","family":"Duque","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-6723","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Marinho","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4879-559X","authenticated-orcid":false,"given":"Paulo","family":"Almeida","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-4325","authenticated-orcid":false,"given":"Raul","family":"Marques Pereira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0181-3081","authenticated-orcid":false,"given":"Rui","family":"Buzaco","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"1126_CR1","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1056\/NEJMct066061","volume":"356","author":"DW Kimberlin","year":"2007","unstructured":"Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356:1338\u201343.","journal-title":"N Engl J Med"},{"key":"1126_CR2","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833\u2013e004833.","journal-title":"BMJ Open"},{"key":"1126_CR3","first-page":"1","volume":"57","author":"R Harpaz","year":"2008","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1\u201330 (quiz CE2\u20134).","journal-title":"MMWR Recomm Rep"},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1017\/S0950268817001546","volume":"145","author":"K Bollaerts","year":"2017","unstructured":"Bollaerts K, Riera-Montes M, Heininger U, Hens N, Souverain A, Verstraeten T, et al. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol Infect. 2017;145:2666\u201377.","journal-title":"Epidemiol Infect"},{"key":"1126_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","volume":"11","author":"D Curran","year":"2022","unstructured":"Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, Van Oorschot D, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11:389\u2013403.","journal-title":"Infect Dis Ther"},{"key":"1126_CR6","doi-asserted-by":"publisher","first-page":"ofac118","DOI":"10.1093\/ofid\/ofac118","volume":"9","author":"A Bhavsar","year":"2022","unstructured":"Bhavsar A, Lonnet G, Wang C, Chatzikonstantinidou K, Parikh R, Brabant Y, et al. Increased risk of herpes zoster in adults \u2265 50 years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis. 2022;9:ofac118.","journal-title":"Open Forum Infect Dis"},{"key":"1126_CR7","unstructured":"European Medicines Agency. Shingrix: EPAR\u2014product information. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf. Accessed 13 Nov 2024."},{"key":"1126_CR8","unstructured":"European Medicines Agency. Zostavax: EPAR\u2014product information. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zostavax-epar-product-information_en.pdf. Accessed 06 Nov 2024."},{"key":"1126_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, D\u00edez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019\u201332.","journal-title":"N Engl J Med"},{"key":"1126_CR10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087\u201396.","journal-title":"N Engl J Med"},{"key":"1126_CR11","doi-asserted-by":"publisher","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","volume":"9","author":"A Strezova","year":"2022","unstructured":"Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis. 2022;9:ofac485.","journal-title":"Open Forum Infect Dis"},{"key":"1126_CR12","unstructured":"European Medicines Agency. Shingrix: EPAR\u2014risk-management-plan summary. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/shingrix-epar-risk-management-plan-summary_en.pdf. Accessed 13 Nov 2024."},{"key":"1126_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271\u201384.","journal-title":"N Engl J Med"},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years. Clin Infect Dis. 2012;54:922\u20138.","journal-title":"Clin Infect Dis"},{"key":"1126_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900\u20139.","journal-title":"Clin Infect Dis"},{"key":"1126_CR16","unstructured":"European Medicines Agency. Zostavax-H-C-674-II-0003: EPAR\u2014scientific discussion\u2014variation. 2007. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion-variation\/zostavax-h-c-674-ii-0003-epar-scientific-discussion-variation_en.pdf. Accessed 13 Nov 2024."},{"key":"1126_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00103-019-02882-5","volume":"62","author":"A Siedler","year":"2019","unstructured":"Siedler A, Koch J, Garbe E, Hengel H, Von Kries R, Ledig T, et al. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Bundesgesundheitsbl. 2019;62:352\u201376.","journal-title":"Bundesgesundheitsbl"},{"key":"1126_CR18","unstructured":"Ministerio de Sanidad. Recomendaciones de vacunacion frente a herpes zoster. 2023. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/programasDeVacunacion\/docs\/HerpesZoster_RecomendacionesVacunacion.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR19","doi-asserted-by":"publisher","first-page":"101923","DOI":"10.1016\/j.pmedr.2022.101923","volume":"29","author":"NR Meredith","year":"2022","unstructured":"Meredith NR, Armstrong EP. Cost-effectiveness of herpes zoster vaccines in the US: a systematic review. Prev Med Rep. 2022;29:101923.","journal-title":"Prev Med Rep."},{"key":"1126_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/vaccines12080872","volume":"12","author":"J Wang","year":"2024","unstructured":"Wang J, Jin P, Jin H, Wang Q, Zhu F, Li J. Cost-effectiveness analysis of herpes zoster vaccination in a Chinese population: recombinant subunit vaccine versus live attenuated vaccine. Vaccines. 2024;12:872.","journal-title":"Vaccines"},{"key":"1126_CR21","unstructured":"Health Council of the Netherlands. Vaccination against shingles. 2019. https:\/\/www.healthcouncil.nl\/documents\/advisory-reports\/2019\/07\/15\/vaccination-of-older-people-against-shingles. Accessed 05 Nov 2024."},{"key":"1126_CR22","unstructured":"Folkh\u00e4lsomyndigheten. Health economic evaluation of a herpes zoster vaccination programme for the elderly in Sweden. 2024. https:\/\/www.folkhalsomyndigheten.se\/contentassets\/edb20910b1484288ab56e7d7f354e79c\/health-economic-evaluation-herpes-zoster-vaccination-programme-elderly.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR23","first-page":"180","volume":"30","author":"S Duque","year":"2023","unstructured":"Duque S, Marinho A, Almeida P, Marques Pereira R, Buzaco R. Recomenda\u00e7\u00f5es para a Vacina\u00e7\u00e3o contra o Herpes Zoster: Documento de Consenso da Sociedade Portuguesa de Medicina Interna e da Associa\u00e7\u00e3o Portuguesa de Medicina Geral e Familiar. Med Interna. 2023;30:180\u201391.","journal-title":"Med Interna"},{"key":"1126_CR24","unstructured":"European Centre for Disease Prevention and Control. Vaccine Scheduler. 2024. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=51&SelectedCountryIdByDisease=-1. Accessed 05 Nov 2024."},{"key":"1126_CR25","unstructured":"Bundesministerium f\u00fcr Soziales, Gesundheit, Pflege und Konsumentenschutz. Impfplan \u00d6sterreich 2024\/2025. 2024. https:\/\/www.sozialministerium.at\/dam\/jcr:32a90bf4-6728-432e-ae5b-f52bd07c25c0\/Impfplan_\u00d6sterreich_2023_2024_Version_2.0_vom_14.5.2024_pdfUA.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17843286.2024.2350258","volume":"79","author":"AF Nikkels","year":"2024","unstructured":"Nikkels AF, Schoevaerdts D, Kauffmann F, Strubbe F, Bensemmane S. Herpes zoster in Belgium: a new solution to an old problem. Acta Clin Belg. 2024;79:205\u201316.","journal-title":"Acta Clin Belg"},{"key":"1126_CR27","unstructured":"Superior Health Council. Vaccination against Herpes Zoster. 2022. https:\/\/www.health.belgium.be\/sites\/default\/files\/uploads\/fields\/fpshealth_theme_file\/20220906_shc-9684_herpes_zoster_vweb.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR28","unstructured":"Czech Vaccination Society. Recommendations of the Czech Vaccination Society for vaccination against herpes zoster. 2023. https:\/\/vakcinace.eu\/doporuceni-a-stanoviska\/doporuceni-ceske-vakcinologicke-spolecnosti-cls-jep-pro-ockovani-proti-pasovemu-oparu-herpes-zoster. Accessed 05 Nov 2024."},{"key":"1126_CR29","unstructured":"Statens Serum Institut. Helvedesildvaccine (Shingrix). 2024. https:\/\/www.ssi.dk\/vaccinationer\/vaccineleksikon\/h\/helvedesildvaccine-shingrix. Accessed 11 Nov 2024."},{"key":"1126_CR30","unstructured":"MesVaccins\u2014Zostavax. 2024. https:\/\/www.mesvaccins.net\/web\/vaccines\/161-zostavax. Accessed 05 Nov 2024."},{"key":"1126_CR31","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Recommandations vaccinales contre le Zona. Place du vaccin Shingrix. 2024. https:\/\/www.has-sante.fr\/jcms\/p_3498915\/fr\/recommandations-vaccinales-contre-le-zona-place-du-vaccin-shingrix#:~:text=La%20HAS%20recommande%20la%20vaccination,avant%20l\u2019initiation%20du%20traitement. Accessed 05 Nov 2024."},{"key":"1126_CR32","unstructured":"MesVaccins\u2014Shingrix. 2024. https:\/\/www.mesvaccins.net\/web\/vaccines\/567-shingrix. Accessed 05 Nov 2024."},{"key":"1126_CR33","unstructured":"Gemeinsamer Bundesausschuss. Geschaeftsbericht. 2019. https:\/\/www.g-ba.de\/downloads\/17-98-5009\/2020-07-23_G-BA_Geschaeftsbericht_2019_bf.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR34","unstructured":"Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Translation of the original Recommendations of the STIKO at the Robert Koch Institute. 2023. https:\/\/www.rki.de\/EN\/Content\/infections\/Vaccination\/recommandations\/04_23_englisch.pdf?__blob=publicationFile. Accessed 05 Nov 2024."},{"key":"1126_CR35","unstructured":"Ministry of Health of Greece. National Adult Vaccination Programme 2024. Timeline and recommendations. 2024. https:\/\/diavgeia.gov.gr\/decision\/view\/\u03a8\u039c16465\u03a6\u03a5\u039f-\u039f\u03a6\u039a. Accessed 05 Nov 2024."},{"key":"1126_CR36","unstructured":"National Immunisation Advisory Committee. Immunization guidelines. Chapter 23: Varicella-Zoster. 2024. https:\/\/rcpi.access.preservica.com\/uncategorized\/IO_25b10390-0f88-468b-a98a-5ab940f94d1d\/. Accessed 05 Nov 2024."},{"key":"1126_CR37","unstructured":"Ministero della Salute. Calendario nazionale vaccinale. 2023. https:\/\/www.trovanorme.salute.gov.it\/norme\/dettaglioAtto?id=95963&articolo=3#articoli. Accessed 05 Nov 2024."},{"key":"1126_CR38","unstructured":"Direction de la Sant\u00e9, Division de la Pharmacie et des M\u00e9dicaments, du Minist\u00e8re de la s\u00e9curit\u00e9 sociale et de la Caisse nationale de sant\u00e9. Liste des m\u00e9dicaments commercialis\u00e9s valable au 1er d\u00e9cembre 2023. 2023. https:\/\/cns.public.lu\/dam-assets\/legislations\/texte-coordonne\/liste-positive\/2312\/2312-liste-comm.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR39","unstructured":"Conseil Sup\u00e9rieur des Maladies Infectieuses. Recommandations du Conseil sup\u00e9rieur des maladies infectieuses concernant la vaccination contre le zona. 2022. https:\/\/sante.public.lu\/dam-assets\/fr\/espace-professionnel\/recommandations\/conseil-maladies-infectieuses\/zona\/csmi-recommandation-vaccination-zona-vf.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR40","unstructured":"Gouvernement Luxembourgeois. Mise \u00e0 disposition gratuite du vaccin contre le zona pour les personnes \u00e2g\u00e9es de 65 ans et plus, et pour les personnes avec des immunod\u00e9ficiences. 2023. https:\/\/gouvernement.lu\/fr\/actualites\/toutes_actualites\/communiques\/2023\/04-avril\/12-vaccin-gratuit-zona.html. Accessed 05 Nov 2024."},{"key":"1126_CR41","unstructured":"Zorginstituut Nederland. GVS advice RZV (Shingrix\u00ae) for the prevention of herpes zoster and related post-herpetic neuralgia. 2021. https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2021\/06\/14\/gvs-advice-shingrix. Accessed 05 Nov 2024."},{"key":"1126_CR42","unstructured":"Legemiddelsok\u2014Zostavax. 2024. https:\/\/www.legemiddelsok.no\/sider\/Legemiddelvisning.aspx?pakningId=f1160786-1468-419b-9bed-251bf3aeb32d&searchquery=J07BK02&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0. Accessed 05 Nov 2024."},{"key":"1126_CR43","unstructured":"Folkehelseinstituttet. Varicella\u2014og herpes zoster-vaksine\u2014veileder for helsepersonell. 2024. https:\/\/www.fhi.no\/va\/vaksinasjonsveilederen-for-helsepersonell\/vaksiner-mot-de-enkelte-sykdommene\/varicella--og-herpes-zostervaksinas\/?term=#vaksiner-mot. Accessed 05 Nov 2024."},{"key":"1126_CR44","unstructured":"Legemiddelsok\u2014Shingrix. 2024. https:\/\/www.legemiddelsok.no\/sider\/Legemiddelvisning.aspx?pakningId=420accc2-2e7a-43d3-926b-c9cea7636366&searchquery=J07BK03&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0. Accessed 05 Nov 2024."},{"key":"1126_CR45","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.vaccine.2024.02.022","volume":"42","author":"M Rz\u0105d","year":"2024","unstructured":"Rz\u0105d M, Kanecki K, Lewtak K, Tyszko P, Gorynski P, Nitsch-Osuch A. Hospitalizations of patients with herpes zoster in Poland during 2012\u20132021: a population-based study. Vaccine. 2024;42:1928\u201333.","journal-title":"Vaccine"},{"key":"1126_CR46","unstructured":"Kuchar E., Rudnicka L., Kocot-K\u0119pska M. i wsp.: Szczepienie przeciwko p\u00f3\u0142pa\u015bcowi. Zalecenia grupy ekspert\u00f3w Polskiego Towarzystwa Wakcynologii, Polskiego Towarzystwa Medycyny Rodzinnej, Polskiego Towarzystwa Dermatologicznego, Polskiego Towarzystwa Badania B\u00f3lu i Polskiego Towarzystwa Neurologicznego. Med. Prakt. 2023;5:64\u201372."},{"key":"1126_CR47","unstructured":"Nacionalni In\u0161titut za Javno Zdravje. Priporo\u010dila za cepljenje proti herpes zostru. 2024. https:\/\/nijz.si\/wp-content\/uploads\/2024\/09\/Priporocila-za-cepljenje-proti-herpes-zostru-1.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR48","unstructured":"Ministerio de Sanidad. VACUNACI\u00d3N ESPEC\u00cdFICA EN PERSONAS ADULTAS (\u2265 18 A\u00d1OS) CON CONDICIONES DE RIESGO. 2024. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/calendario\/docs\/CalendarioVacunacion_GRadultos.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR49","unstructured":"Ministerio de Sanidad. Calendario com\u00fan de vacunaciones e inmunizaciones a lo largo de toda la vida. 2024. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/calendario\/docs\/CalendarioVacunacion_Todalavida.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR50","unstructured":"Folkh\u00e4lsomyndigheten. Vaccination mot b\u00e4ltros. 2024. https:\/\/www.folkhalsomyndigheten.se\/smittskydd-beredskap\/vaccinationer\/vacciner-som-anvands-i-sverige\/baltros\/. Accessed 05 Nov 2024."},{"key":"1126_CR51","unstructured":"Office f\u00e9d\u00e9ral de la sant\u00e9 publique. La r\u00e9vision de la liste des moyens et appareils est termin\u00e9e. 2021. https:\/\/www.admin.ch\/gov\/fr\/accueil\/documentation\/communiques.msg-id-86279.html. Accessed 06 Nov 2024."},{"key":"1126_CR52","unstructured":"Office f\u00e9d\u00e9ral de la sant\u00e9 publique. Plan de vaccination suisse 2024. 2024. https:\/\/www.bag.admin.ch\/dam\/bag\/fr\/dokumente\/mt\/i-und-b\/richtlinien-empfehlungen\/neue-empfehlungen\/schweizerischer-impfplan.pdf.download.pdf\/schweizerischer-impfplan-de.pdf. Accessed 06 Nov 2024."},{"key":"1126_CR53","unstructured":"National Health Service England. Changes to the GP Contract in 2023\/24. 2023. https:\/\/www.england.nhs.uk\/long-read\/changes-to-the-gp-contract-in-2023-24\/#annex-a-changes-to-the-gp-contract-in-2023-24. Accessed 06 Nov 2024."},{"key":"1126_CR54","unstructured":"UK Health Security Agency. Immunisation against infectious disease\u2014The Green Book. [ebook] London: PHE. Chapter 28a\u2014Shingles (herpes zoster). 2024. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1174008\/Shingles_Green_Book_on_Immunisation_Chapter_28a_26_7_23.pdf. Accessed 06 Nov 2024."},{"key":"1126_CR55","unstructured":"Centers for Disease Control and Prevention. Shingles vaccine recommendations. 2024. https:\/\/www.cdc.gov\/shingles\/hcp\/vaccine-considerations\/index.html. Accessed 06 Nov 2024."},{"key":"1126_CR56","unstructured":"Infomed. Detalhes do Medicamento: Zostavax. 2024. https:\/\/extranet.infarmed.pt\/INFOMED-fo\/detalhes-medicamento.xhtml. Accessed 06 Nov 2024."},{"key":"1126_CR57","unstructured":"Regione Liguria\u2014Giunta Regionale. Recepimento della Intesa Stato-Regioni\/PP.AA. (Rep. Atti n. 193\/CSR 2 agosto 2023)\u2014\u201cPiano nazionale di prevenzione vaccinale (PNPV) 2023\u20132025\u201d e approvazione del Calendario vaccinale regionale della Liguria, aggiornamento 2023. 2023. https:\/\/www.vaccinarsinliguria.org\/assets\/uploads\/files\/8\/dgr-n-916-del-25-09-2023.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR58","unstructured":"Servizio Sanitario Regionale Emilia-Romagna.VACCINAZIONE ANTI-HERPES ZOSTER. 2024. https:\/\/www.ausl.bologna.it\/cit\/vaccini\/adulti\/schede-vaccini-adulti\/scheda-vaccin-antiherpes-zoster-2014.pdf. Accessed 05 Nov 2024."},{"key":"1126_CR59","unstructured":"Sistema Socio Sanitario Regione Lombardia. VACCINAZIONE ANTI HERPES ZOSTER. 2022. https:\/\/www.asst-crema.it\/contenuto-web\/-\/asset_publisher\/EXTdn8PnFIax\/content\/vaccinazione-anti-herpes-zoster. Accessed 05 Nov 2024."},{"key":"1126_CR60","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/14760584.2021.1956906","volume":"20","author":"R Parikh","year":"2021","unstructured":"Parikh R, Widenmaier R, Lecrenier N. A practitioner\u2019s guide to the recombinant zoster vaccine: review of national vaccination recommendations. Expert Rev Vaccines. 2021;20:1065\u201375.","journal-title":"Expert Rev Vaccines"},{"key":"1126_CR61","doi-asserted-by":"publisher","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","volume":"7","author":"F Marra","year":"2020","unstructured":"Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7:ofaa005.","journal-title":"Open Forum Infect Dis"},{"key":"1126_CR62","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","volume":"15","author":"L Oostvogels","year":"2019","unstructured":"Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, et al. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019;15:2865\u201372.","journal-title":"Hum Vaccin Immunother"},{"key":"1126_CR63","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade. Avalia\u00e7\u00e3o do Programa Nacional de Vacina\u00e7\u00e3o\u20142o Inqu\u00e9rito Serol\u00f3gico Nacional Portugal Continental 2001\u20132002. 2004. https:\/\/www.dgs.pt\/upload\/membro.id\/ficheiros\/i009552.pdf. Accessed 07 Nov 2024."},{"key":"1126_CR64","unstructured":"\u00cdndex das Revistas M\u00e9dicas Portuguesas. Artigos Destacados. 2024. https:\/\/www.indexrmp.pt\/destaques. Accessed 06 Nov 2024."},{"key":"1126_CR65","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","volume":"19","author":"AF Dagnew","year":"2019","unstructured":"Dagnew AF, Ilhan O, Lee W-S, Woszczyk D, Kwak J-Y, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19:988\u20131000.","journal-title":"Lancet Infect Dis"},{"key":"1126_CR66","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","volume":"60","author":"AF Dagnew","year":"2021","unstructured":"Dagnew AF, Rausch D, Herv\u00e9 C, Zahaf T, Levin MJ, Schuind A, et al. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology. 2021;60:1226\u201333.","journal-title":"Rheumatology"},{"key":"1126_CR67","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, L\u00f3pez-Jim\u00e9nez J, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322:123.","journal-title":"JAMA"},{"key":"1126_CR68","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade. Programa Nacional de Vacina\u00e7\u00e3o 2020: Atualiza\u00e7\u00e3o 06\/10\/2023. 2023. https:\/\/www.sns24.gov.pt\/tema\/vacinas\/programa-nacional-de-vacinacao\/. Accessed 06 Nov 2024."},{"key":"1126_CR69","unstructured":"Eurostat. Population structure and ageing. 2024. https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Population_structure_and_ageing. Accessed 06 Nov 2024."}],"container-title":["Drugs & Therapy Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-024-01126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40267-024-01126-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-024-01126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T16:24:18Z","timestamp":1738167858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40267-024-01126-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1007\/s40267-024-01126-0","relation":{},"ISSN":["1172-0360","1179-1977"],"issn-type":[{"value":"1172-0360","type":"print"},{"value":"1179-1977","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"21 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by FCT|FCCN (b-on). This study was funded by GlaxoSmithKline, which had no role in decisions about the content of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SD, AM, PA, and RB have received lecture fees from GlaxoSmithKline. RMP has no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This article was developed based on input from the expert advisors (SD, AM, PA, RMP, and RB), who attended three virtual roundtable meetings in February and March 2023. All authors made substantial contributions to the preparation of this article, critical evaluation, and revision of all drafts. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}